Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 02, 2016

Final 5-Year Study Results: Dasatinib vs Imatinib in Chronic Myeloid Leukemia

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
J. Clin. Oncol 2016 May 23;[EPub Ahead of Print], JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, NP Shah, C Chuah, L Casanova, B Bradley-Garelik, G Manos, A Hochhaus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading